Leukadherin-1 (LA1), a novel small molecule agonist of integrin CD11b/CD18, can increase the extent of CD11b/CD18-dependent cell adhesion of transfected cells and of primary human and mouse neutrophils (EC50 =4µM in vitro), which resulted in decreased chemotaxis and transendothelial migration. LA1 can also decrease leukocyte recruitment and reduced arterial narrowing after injury in rats. Moreover, compared to a known integrin antagonist, LA1 preserved kidney function better in a mouse model of experimental nephritis. It inhibited leukocyte recruitment by increasing leukocyte adhesion to the inflamed endothelium, which was reversed with a blocking antibody.
Technical information:
| Chemical Formula: | C22H15NO4S2 | |
| CAS #: | 344897-95-6 | |
| Molecular Weight: | 421.49 | |
| Purity: | >98% | |
| Appearance: | White solid | |
| Chemical Name: | (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| Solubility: | Up to 50 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Dony Maiguel, et al. Small Molecule–Mediated Activation of the Integrin CD11b/CD18 Reduces Inflammatory Disease. Sci. Signal., Vol. 4, Issue 189, p. ra57 |
| 2. | Faridi MH et al. Identification of novel agonists of the integrin CD11b/CD18. Bioorg Med Chem Lett. 2009; 19(24):6902-6. |
Other Information:
Product Specification (pdf)
MSDS (pdf)
